drugset / Trial / NCT00625742

Multimodal Treatment Strategy for Cancer Cachexia

NCT00625742

Terminated 15 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The primary aim of this proposal is to present a novel, multimodal treatment strategy for increasing lean body mass in individuals with cancer who experience cachexia between baseline and day 29 (+/- 3 days). The strategy includes graded resistance training and aerobic exercise, targeted nutrient supplementation and pharmacologic intervention (melatonin). We postulate that this strategy, together with the simultaneous management of symptoms that decrease appetite (e.g. depression, pain, and nausea), will also accomplish our secondary objectives of improving clinical outcomes such as strength and function between baseline and day 29 (+/- 3 days).

Timeline

Start
2008-02
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject .BETA.-HYDROXYISOVALERIC ACID Small molecule
Subject Melatonin Small molecule 20 mg Oral
Background Atenolol Other / unclassified
Background Ibuprofen Small molecule 400 mg